GSK PLC Sponsored ADR (GSK) To Go Ex-Dividend on November 13th

GSK PLC Sponsored ADR (NYSE:GSK) announced a quarterly dividend on Wednesday, October 28th. Investors of record on Friday, November 13th will be paid a dividend of $0.4518 per share by the pharmaceutical company on Thursday, January 7th. This represents a $1.81 annualized dividend and a yield of 3.7%. The ex-dividend date is Friday, November 13th. This is a 0.1% increase from GSK’s previous quarterly dividend of $0.4515.

GSK has decreased its dividend payment by an average of 0.1% per year over the last three years. GSK has a dividend payout ratio of 36.6% meaning its dividend is sufficiently covered by earnings. Research analysts expect GSK to earn $5.00 per share next year, which means the company should continue to be able to cover its $1.77 annual dividend with an expected future payout ratio of 35.4%.

GSK Trading Down 0.2%

GSK stock opened at $48.62 on Friday. The business has a fifty day moving average price of $49.49 and a 200 day moving average price of $52.35. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. GSK has a fifty-two week low of $45.81 and a fifty-two week high of $61.69. The stock has a market capitalization of $98.35 billion, a price-to-earnings ratio of 16.90, a P/E/G ratio of 2.12 and a beta of 0.33.

GSK (NYSE:GSK) last issued its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. GSK had a net margin of 13.00% and a return on equity of 42.41%. GSK’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.47 earnings per share. Analysts expect that GSK will post 4.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on GSK. Royal Bank Of Canada initiated coverage on shares of GSK in a report on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Morgan Stanley restated an “underweight” rating on shares of GSK in a research report on Tuesday, August 25th. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of GSK in a research note on Thursday, October 1st. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and lowered their target price for the company from $67.40 to $55.90 in a research note on Thursday. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of GSK in a report on Tuesday. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $56.30.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.